News

Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications

Preclinical data shows precision modulation of beta-2 and beta-3 signaling boosts metabolismand enhances body recomposition STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) — Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of Molecular Metabolism (1). The research paper validates the mechanism of action of the company’s […]

Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications Read More »

Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

All endpoints met for novel b2–adrenoceptor agonist ATR-258 treating root cause of T2D Solna, Sweden 14 March 2024 – Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial,

Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes Read More »

Atrogi announces first patient treated with Adrenoceptor agonist

first patient treated witH ATR-258 ß\2\ adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Atrogi announced today that the first patient has been enrolled in a Phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel ß2 adrenoceptor agonist with a unique mechanism of action for the

Atrogi announces first patient treated with Adrenoceptor agonist Read More »

New patent granted

Atrogi is developing novel compounds and treatments of metabolic disorders and a robust patent portfolio has been generated to develop the commercial asset and increase value. Several patents have already been granted; here are two of the more recent from June and August. US 11,357,757Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycemia US 11,427,539 Beta-hydroxy heterocyclic

New patent granted Read More »

Anders Ekblom as new chairman of the board

Atrogi welcomes Anders Ekblom as the new chairman of the board. Anders Ekblom has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management. He is currently Chairman/Non-Executive Board member of several biotech companies namely AnaMar AB, Alligator Bioscience AB,

Anders Ekblom as new chairman of the board Read More »

Atrogi receives Eurostars grant to develop obesity project

Atrogi is one of a few companies to be selected for a prestigious grant from Eurostars, an initiative of the European Commission that promotes research, and the intergovernmental innovation network EUREKA. The application was done in consortium with Stockholm University, Maastricht University, the Latvian Institute of Organic Synthesis and Excellerate Bioscience. The grant awarded is

Atrogi receives Eurostars grant to develop obesity project Read More »

BIO-Europe 2017 in Berlin

Atrogi participated in BIO-Europe 2017 in Berlin, which is the largest partnering meeting in Europe. The purpose was to present our type 2 diabetes project to pharmaceutical companies. At the meeting Atrogi met with several of the largest companies that are working in the diabetes area. The response was overwhelming and Atrogi will follow up the requests for information.

BIO-Europe 2017 in Berlin Read More »